MG
NKTR icon

Michael Gelband’s Nektar Therapeutics NKTR Stock Holding History

Michael Gelband’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.08M Buy
58,507
+38,050
+186% +$2.78M 0.03% 561
2026
Q1 		$1.47M Buy
+20,457
New +$1.16M 0.01% 883
2024
Q4 		– Sell
-18,691
Closed -$364K – 1877
2024
Q3 		$364K Buy
+18,691
New +$356K ﹤0.01% 1296
2023
Q1 		– Sell
-32,833
Closed -$1.11M – 2011
2022
Q4 		$1.11M Buy
32,833
+30,763
+1,486% +$1.49M 0.02% 894
2022
Q3 		$99K Buy
+2,070
New +$123K ﹤0.01% 1746
2022
Q2 		– Sell
-27,714
Closed -$2.24M – 2272
2022
Q1 		$2.24M Buy
27,714
+26,322
+1,891% +$3.9M 0.03% 721
2021
Q4 		$282K Sell
1,392
-2,392
-63% -$519K ﹤0.01% 1686
2021
Q3 		$1.02M Buy
3,784
+920
+32% +$221K 0.01% 1017
2021
Q2 		$737K Buy
+2,864
New +$793K 0.01% 1160
2021
Q1 		– Sell
-1,103
Closed -$281K – 2440
2020
Q4 		$281K Sell
1,103
-2,264
-67% -$585K ﹤0.01% 1576
2020
Q3 		$838K Buy
3,367
+996
+42% +$313K 0.02% 762
2020
Q2 		$824K Buy
+2,371
New +$740K 0.02% 839
2020
Q1 		– Sell
-2,752
Closed -$891K – 1462
2019
Q4 		$891K Buy
+2,752
New +$798K 0.02% 602

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's NKTR Position: Q2 2026 in Review

Michael Gelband increased its Nektar Therapeutics (NKTR) stake by 186% in Q2 2026, buying an estimated $2.78M and bringing the position to 58,507 shares worth $4.08M. The position accounts for 0.03% of the portfolio, ranked #561.

Michael Gelband first reported a position in NKTR in Q4 2019 and has held it in 13 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Michael Gelband held 58,507 shares of Nektar Therapeutics worth $4.08M as of Q2 2026.
  • Michael Gelband bought 38,050 Nektar Therapeutics shares in Q2 2026, an estimated $2.78M.
  • Nektar Therapeutics made up 0.03% of Michael Gelband's portfolio in Q2 2026, its #561 holding.
  • Michael Gelband first reported a position in Nektar Therapeutics in Q4 2019 and has held it in 13 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.